Last Updated: November 16, 2026

Investigational Drug Information for Elobixibat

« Back to Dashboard


What is the development status for investigational drug Elobixibat?

Elobixibat is an investigational drug.

There have been 13 clinical trials for Elobixibat. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2021.

The most common disease conditions in clinical trials are Constipation, Non-alcoholic Fatty Liver Disease, and Liver Diseases. The leading clinical trial sponsors are Ferring Pharmaceuticals, Yokohama City University, and Albireo.

There are two hundred and eighty US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Elobixibat
TitleSponsorPhase
Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol RegimenDepartment of Medical Services Ministry of Public Health of ThailandNA
Elobixibat for Chronic Constipation Without Defecation DesireInternational University of Health and WelfarePhase 4
Elobixibat for Chronic Constipation Without Defecation DesireYokohama City UniversityPhase 4

See all Elobixibat clinical trials

Clinical Trial Summary for Elobixibat

Top disease conditions for Elobixibat
Top clinical trial sponsors for Elobixibat

See all Elobixibat clinical trials

US Patents for Elobixibat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Elobixibat ⤷  Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) ⤷  Start Trial
Elobixibat ⤷  Start Trial IBAT inhibitors for the treatment of liver diseases Albireo AB (Gothenburg, SE) ⤷  Start Trial
Elobixibat ⤷  Start Trial Branched 3-phenylpropionic acid derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (Monheim, DE) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.